Vidcast:  https://youtu.be/_bmcDkp7_5Q

 

The skin cancer melanoma is a vicious disease that metastasizes and kills.  Moderna, the CoVid mRNA vaccine company, has now partnered with Merck, the maker of the checkpoint inhibitor Keytruda, to create a novel immunotherapeutic regimen that cuts the risk of Stage 3/4 melanoma recurrence or death by 44%.  This impressive result was demonstrated in a Phase 2 study headed by NYU oncologist Jeffrey Weber, MD, PhD.  Moderna’s mRNA melanoma vaccine is individualized for each patient. It contains mRNA that codes for the patients own tumor proteins.  The vaccine then stimulates a vigorous immune response to a patient’s own melanoma while the checkpoint inhibitor Keytruda blocks the melanoma’s attempts to thwart a vigorous immune attack.

 

http://bitly.ws/z5iu

 

#melanoma #vaccine #checkpointinhibitor #moderna #merck #immunotherapy